Peptide Array Immunodiagnosis for Chronic Fatigue Syndrome

The patent introduces peptide arrays as an intermediary diagnostic tool between clinical assessment and definitive diagnosis. The peptide arrays serve as a mediator that captures antibody profiles, transforming subjective clinical symptoms into objective measurable immunosignatures. This intermediary system bridges the gap between simple clinical evaluation and complex biomarker analysis, enabling accurate diagnosis without requiring direct identification of all underlying pathological proteins.

The patent replaces subjective clinical judgment (mechanical/physical assessment) with immunological measurement systems. Instead of relying on physician assessment of symptoms, the diagnostic approach substitutes objective measurement of antibody-peptide binding interactions. This substitution transforms a subjective mechanical diagnostic process into an objective biochemical measurement system with quantifiable results.

The patent inverts the traditional biomarker identification approach. Instead of directly identifying and measuring pathological proteins (the conventional approach), the method measures antibodies that bind to peptide arrays representing potential antigens. This inversion allows identification of disease-associated antibody profiles without requiring direct isolation or characterization of the underlying pathological proteins, significantly reducing time and complexity.

The patent uses peptide copies synthesized on arrays as representations of actual pathological proteins. Rather than working with the complex, often unavailable native proteins directly involved in CFS pathology, the method creates simplified peptide copies that retain the antigenic epitopes. These peptide copies serve as surrogates that can be easily synthesized, immobilized, and measured, providing the same diagnostic information without the complexity of handling native proteins.